Literature DB >> 11779034

Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors.

N Zaveri1, W E Polgar, C M Olsen, A B Kelson, P Grundt, J W Lewis, L Toll.   

Abstract

Nociceptin/orphanin FQ (N/OFQ) was recently identified as the endogenous ligand for the opioid-receptor like (ORL1) receptor. Although the ORL1 receptor shows sequence homology with the opioid receptors, the nociceptin/ORL1 ligand-receptor system has very distinct pharmacological actions compared to the opioid receptor system. Recently, several small-molecule ORLI receptor ligands were reported by pharmaceutical companies. Most of these ligands had close structural similarities with known neuroleptics and opiates. In this study, we screened several available neuroleptics and opiates for their binding affinity and functional activity at ORL1 and the opioid receptors. We also synthesized several analogs of known opiates with modified piperidine N-substituents in order to characterize the ORL1 receptor ligand binding pocket. Substitution with the large, lipophilic cyclooctylmethyl moiety increased ORL1 receptor affinity and decreased mu receptor affinity and efficacy in the fentanyl series of ligands but had a different effect in the oripavine class of opiate ligands. Our results indicate that opiates and neuroleptics may be good starting points for ORL1 receptor ligand design, and the selectivity may be modulated by appropriate structural modifications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11779034      PMCID: PMC3852903          DOI: 10.1016/s0014-2999(01)01282-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  26 in total

1.  High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor.

Authors:  S Röver; G Adam; A M Cesura; G Galley; F Jenck; F J Monsma; J Wichmann; F M Dautzenberg
Journal:  J Med Chem       Date:  2000-04-06       Impact factor: 7.446

2.  Effects of sigma ligands on the nociceptin/orphanin FQ receptor co-expressed with the G-protein-activated K+ channel in Xenopus oocytes.

Authors:  T Kobayashi; K Ikeda; S Togashi; N Itoh; T Kumanishi
Journal:  Br J Pharmacol       Date:  1997-03       Impact factor: 8.739

3.  Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ.

Authors:  J S Mogil; J E Grisel; G Zhangs; J K Belknap; D K Grandy
Journal:  Neurosci Lett       Date:  1996-08-23       Impact factor: 3.046

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  Synthetic analgesics: N-(1-[2-arylethyl]-4-substituted 4-piperidinyl) N-arylalkanamides.

Authors:  P G Van Daele; M F De Bruyn; J M Boey; S Sanczuk; J T Agten; P A Janssen
Journal:  Arzneimittelforschung       Date:  1976

6.  Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids.

Authors:  J L Butour; C Moisand; H Mazarguil; C Mollereau; J C Meunier
Journal:  Eur J Pharmacol       Date:  1997-02-19       Impact factor: 4.432

7.  Effects of intrathecally administered nociceptin, an opioid receptor-like1 (ORL1) receptor agonist, on the thermal hyperalgesia induced by unilateral constriction injury to the sciatic nerve in the rat.

Authors:  T Yamamoto; N Nozaki-Taguchi; S Kimura
Journal:  Neurosci Lett       Date:  1997-03-14       Impact factor: 3.046

8.  New 4-(heteroanilido)piperidines, structurally related to the pure opioid agonist fentanyl, with agonist and/or antagonist properties.

Authors:  J R Bagley; R L Wynn; F G Rudo; B M Doorley; H K Spencer; T Spaulding
Journal:  J Med Chem       Date:  1989-03       Impact factor: 7.446

9.  New 1-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics.

Authors:  J R Bagley; S A Thomas; F G Rudo; H K Spencer; B M Doorley; M H Ossipov; T P Jerussi; M J Benvenga; T Spaulding
Journal:  J Med Chem       Date:  1991-02       Impact factor: 7.446

10.  Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

Authors:  J R Traynor; S R Nahorski
Journal:  Mol Pharmacol       Date:  1995-04       Impact factor: 4.436

View more
  25 in total

1.  Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at mu and delta opioid receptors.

Authors:  Yeon Sun Lee; Joel Nyberg; Sharif Moye; Richard S Agnes; Peg Davis; Shou-wu Ma; Josephine Lai; Frank Porreca; Ruben Vardanyan; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2007-02-08       Impact factor: 2.823

2.  14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.

Authors:  Nick P R Nieland; David Rennison; Jillian H Broadbear; Lauren Purington; James H Woods; John R Traynor; John W Lewis; Stephen M Husbands
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

3.  Nociceptin produces antinociception after spinal administration in amphibians.

Authors:  Craig W Stevens; Kristin K Martin; Brad W Stahlheber
Journal:  Pharmacol Biochem Behav       Date:  2008-09-05       Impact factor: 3.533

4.  A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.

Authors:  Huiping Ding; Norikazu Kiguchi; Dennis Yasuda; Pankaj R Daga; Willma E Polgar; James J Lu; Paul W Czoty; Shiroh Kishioka; Nurulain T Zaveri; Mei-Chuan Ko
Journal:  Sci Transl Med       Date:  2018-08-29       Impact factor: 17.956

Review 5.  The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.

Authors:  Nurulain T Zaveri
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

6.  Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.

Authors:  Gerta Cami-Kobeci; Willma E Polgar; Taline V Khroyan; Lawrence Toll; Stephen M Husbands
Journal:  J Med Chem       Date:  2011-09-07       Impact factor: 7.446

7.  A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.

Authors:  Nurulain T Zaveri; Paul V Marquez; Michael E Meyer; Willma E Polgar; Abdul Hamid; Kabirullah Lutfy
Journal:  Alcohol Clin Exp Res       Date:  2018-01-19       Impact factor: 3.455

8.  Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.

Authors:  Colette M Cremeans; Erin Gruley; Donald J Kyle; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2012-06-28       Impact factor: 4.030

9.  Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.

Authors:  David Rennison; Adrian P Neal; Gerta Cami-Kobeci; Mario D Aceto; Fernando Martinez-Bermejo; John W Lewis; Stephen M Husbands
Journal:  J Med Chem       Date:  2007-09-22       Impact factor: 7.446

Review 10.  Pharmacokinetics of non-intravenous formulations of fentanyl.

Authors:  Jörn Lötsch; Carmen Walter; Michael J Parnham; Bruno G Oertel; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.